68100
document
The influence of prostaglandin inhibition by indomethacin on blood pressure and renal function in hypertensive patients treated with cilazapril . 1 . In a placebo-controlled double-blind cross-over study lasting 6 weeks , twenty patients with essential hypertension were treated with placebo for 2 weeks followed by oral cilazapril 2.5 mg once a day or oral indomethacin 50 mg twice daily for 2 weeks . Afterwards they received the combination of both drugs for a further 2 weeks . 2 . Cilazapril significantly lowered systolic and diastolic blood pressure for a period of 24 h post administration . 3 . Indomethacin significantly attenuated the antihypertensive activity of cilazapril . This was more pronounced in those patients who were treated for the initial 2 weeks with indomethacin plus placebo ( and subsequently with cilazapril in addition ) than in the subjects who first received cilazapril plus placebo and then the combination . 4 . Correspondingly the decrease of plasma renin activity ( PRA ) and urinary prostaglandin excretion ( PGE2 ) was more pronounced in those patients treated initially with indomethacin . 5 . The effect of indomethacin on the antihypertensive effect of cilazapril appears to depend upon the sequence of drug administration .
68101
Intervention_Pharmacological
indomethacin
68102
Intervention_Pharmacological
cilazapril
68103
Intervention_Control
placebo-controlled
68104
Intervention_Control
placebo
68105
Intervention_Pharmacological
oral cilazapril
68106
Intervention_Pharmacological
oral indomethacin
68107
Intervention_Pharmacological
Cilazapril
68108
Intervention_Pharmacological
Indomethacin
68109
Intervention_Pharmacological
cilazapril
68110
Intervention_Control
indomethacin plus placebo
68111
Intervention_Pharmacological
cilazapril
68112
Intervention_Control
cilazapril plus placebo
68113
Intervention_Pharmacological
indomethacin
68114
Intervention_Pharmacological
indomethacin
68115
Intervention_Pharmacological
cilazapril
68116
Outcome_Physical
blood pressure
68117
Outcome_Physical
renal function
68118
Outcome_Physical
systolic and diastolic blood pressure
68119
Outcome_Physical
antihypertensive activity
68120
Outcome_Physical
plasma renin activity ( PRA )
68121
Outcome_Physical
urinary prostaglandin excretion ( PGE2 )
68122
Participant_Condition
hypertensive
68123
Participant_Sample-size
twenty
68124
Participant_Condition
essential hypertension